Roche expands the Global Access Program beyond HIV to also include diagnostic tests for Tuberculosis, Hepatitis, and Human Papillomavirus
- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals
- Improving access to reliable diagnostics for disease management in countries with the highest burden
- Early detection of infectious diseases with diagnostics helps clinicians save lives
Basel, 22 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest. The expansion of the Global Access Program highlights Roche’s commitment to improve access to cost-effective resources, implement scale-up programs, and contribute to the elimination of diseases in the regions with the greatest need.
“With effective treatment options for these infectious agents and improved patients access to diagnostics, early detection can help save lives and ease suffering,” said Michael Heuer, CEO Roche Diagnostics. “As the leader in infectious disease diagnosis testing, Roche is dedicated to support goals on eradicating diseases globally.”
“Access to cutting-edge, best in class diagnostic test results means more patients being appropriately diagnosed and well treated, resulting in lives saved,” stated David Ripin, Chief Science Officer of the Clinton Health Access Initiative (CHAI). "We welcome Roche’s decision to expand access to tests for hepatitis, tuberculosis, and HPV (the leading cause of cervical cancer) to their Global Access Program, providing health systems with transparent and consistent pricing to these important tests in addition to the HIV viral load and early infant diagnostics already established in the program. CHAI values Roche’s continued partnership in the effort to make diagnostics seamlessly available in well optimized diagnostic lab systems throughout the world."
“Accessible pricing can be the difference between a patient getting a quality diagnosis or not,” said Catharina Boehme, CEO of the Foundation for Innovative New Diagnostics (FIND) – a global non-profit devoted to the development and delivery of diagnostics for diseases that include TB and HCV. “FIND is proud to have worked with Roche to expand the Global Access Program for these deadly diseases, leveraging our support for its TB assay.”
Access to screening, early detection and prevention of transmission reduces the spread of disease. Tuberculosis is a major health crisis and is the leading cause of infectious disease deaths worldwide. Access to hepatitis diagnostic tests for HBV and HCV will improve the outlook of eliminating these chronic infections. And screening with HPV DNA testing can more accurately identify women at risk for cervical cancer than other screening methods.1 With vaccination and proper screening, cervical cancer is a preventable disease.2 Importantly, infection with HPV has been found to increase the risk of HIV transmission for both men and women.3 Similarly, women living with HIV are four to 10 times more likely to develop cervical cancer.4 Screening for co-infection (HIV+ HPV) can significantly improve disease management decisions and enable appropriate patient care.
In total, the Global Access Program now includes molecular diagnostics for HIV-1 viral load, HIV-1 and HIV-2 early infant diagnosis, the cobas® Plasma Separation Card - an innovative plasma collection device, MTB and MTB - RIF/INH, Hepatitis B and C, and Human Papillomavirus. All these assays run on the cobas® 4800/6800/8800 platforms for various testing volume needs enabled by the cobas® Plasma Separation Card that transports samples from remote areas/sites to the central lab for further processing.
About World Health Organization disease elimination goals
Optimizing the use of diagnostics will be critical to achieving targets for elimination. The UNAIDS HIV 90:90:90 goal by 2020 states that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will have durable viral suppression.
For hepatitis, the World Health Organization defined goals aiming at a 90% reduction in new chronic infections and a 65% reduction in mortality in 2030 as compared with the 2015 baseline.5
Cervical cancer is preventable with vaccination, screening, and treatment when necessary. The draft 2030 goals for cervical cancer elimination include 90% vaccination rate for HPV in girls by 15 years of age, 70% of women screened with a high-precision test at 35 and 45 years of age along with appropriate follow-up, and 90% of women identified with cervical disease receive treatment and care.6
The WHO have established goals to end Mycobacterium tuberculosis by 2035 which includes a 95% reduction in death, 90% reduction in incidence, and 0% catastrophic costs.7
About Roche’s Global Access Program
In 2014, Roche announced, the Global Access Program for increased access to HIV diagnostics. Roche partnered with national governments, local healthcare facilities, communities and international agencies, including UNAIDS, CHAI, Unitaid, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), Global Fund, and Center for Disease Control and Prevention (CDC), to establish programs that would go beyond providing diagnostic tests. Since its inception, the program has expanded substantially in menu and geographic footprint to provide increased access to diagnostics at affordable pricing for qualifying organizations in eligible countries with the highest disease burden. Most recently the Global Access Program included the innovative cobas® Plasma Separation Card to provide the only CE-marked plasma sample collection devise which meets the World Health Organization sensitivity standard of < 1000 cp/mL.
According to the World Health Organization (WHO), there are over 36 million people living with HIV around the world.8 Just 21.7 million people are receiving antiretroviral therapy and of those, only 47% are virally suppressed.9
Tuberculosis is a major global health problem, and is the leading cause of infectious disease deaths worldwide.10 The World Health Organization (WHO) estimates that about 1.7 billion people are infected with MTB, with an estimated 10.0 million new TB infections, and over 1.6 million deaths in 2017.
Viral hepatitis remains a major public health burden killing more than 1.34 million people annually and mortality is on the rise.11 71 million are estimated to be infected with chronic hepatitis C12 ; whereas, 257 million are estimated to be infected with hepatitis B.13 The majority of disease burden is in low- and middle-income countries.
According to the WHO, there are approximately 570,000 new cases of cervical cancer and 311,000 deaths globally each year, with close to 90% of these occurring in low- and middle-income countries.14,15 Human Papillomavirus (HPV) is the cause of nearly all cases so screening for HPV DNA can identify women at risk; with proper vaccination, screening and treatment, nearly 100% of cervical cancers can be eliminated.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
*Not all products and uses are available in all countries. Please refer to the package insert for applicable intended uses for each individual product.
 Wentzensen N, et al. HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev Med. 2017;98:33-5
 https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/ Retreived 08Jul2019
 http://www.unaids.org/en/cervical_cancer . Accessed 1Nov2018
 WHO draft global strategy towards the elimination of cervical cancer as a public health problem https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf. Accessed 11Jun2019.
 WHO. GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 2016–2021. 2016
 Source: WHO draft global strategy towards the elimination of cervical cancer as a public health problem
https://www.who.int/docs/default-source/documents/cervical-cancer-elimination-draft-strategy.pdf Accessed 11Jun2019
 http://www.who.int/tb/post2015_strategy/en/ . Accessed 1Nov2018
 WHO HIV Key Facts. http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids . Accessed 15Oct2018.
  UNAIDS Global HIV & AIDS statistics — 2018 fact sheet. WHO HIV Key Facts.
http://www.who.int/en/news-room/fact-sheets/detail/hiv-aids. Accessed 18Oct2018.
 World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland; WHO, 2018.
 Global Hepatitis Report 2017 - World Health Organization. April 2017
 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176.
 Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018.
 Bray F, Ferlay J, Soerjomataram I, Dikshit R, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians; 68(6): 394-424
 http://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/. Accessed 5Nov2018
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Karsten Kleine
- Barbara von Schnurbein
- Anja von Treskow
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality16.8.2019 17:17:00 CEST | Press release
Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients. The expanded indication approval is based on randomized clinical data from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations (CoreValve™, Evolut™ R, and Evolut™ PRO valves) in more than 1,400 patients. The data showed TAVR to have an excellent safety prof
Banks net position in the Riksbank16.8.2019 16:40:00 CEST | Press release
Aug 16, 2019 SEK MILLION LENDING BORROWING 261
Acacia Pharma Group plc - Issue of Equity on Exercise of Options16.8.2019 16:39:00 CEST | Press release
Cambridge, UK and Indianapolis, US – 16 August 2019: Acacia Pharma Group plc (the "Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 106,997 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s [Enterprise Management Incentive Share Option Plan]. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue. Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,442,417 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of votin
Conditions for Riksbank Bid Procedures Sek Bonds16.8.2019 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-22 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/ -250 Settlement date 2019-08-26 Bids have to be entered by 10.00 on AUG 22, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 22, 2019 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
Correction: Prosafe SE: Publication of Information Memorandum16.8.2019 15:05:00 CEST | Press release
Correction: the Information Memorandum was not attached to the previous announcement, and has now been attached. Not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Reference is made to announcement of 3 June 2019 concerning the merger agreement between Prosafe SE ("Prosafe", OSE ticker PRS) and Floatel International Ltd ("Floatel"). Pursuant to section 3.5 of the Oslo Stock Exchange Continuing Obligations for listed companies, Prosafe has today published an information memorandum in respect of the merger. A copy of the information memorandum is available on www.newsweb.no and on Prosafe's website along with relevant financial reports at the following link: https://www.prosafe.com/information-memorandum/category1096.html Stavanger, 16 August 2019 Prosafe SE For further questions, please contact: Glen Ole Rødland, Chairman of Prosafe: + 47 907 41 662 Jesper K
Avance Gas Holding Ltd - Invitation to Earnings Release Audio Webcast for the Second Quarter of 201916.8.2019 14:38:00 CEST | Press release
Bermuda, 16 August 2019 - Avance Gas Holding Ltd (OSE: "AVANCE"), will on Thursday 22 August 2019 release its unaudited results for the second quarter of 2019. In connection with the earnings release, an audio webcast and conference call will be held at 15:00 (CET). The webcast can be accessed at Avance Gas' website www.avancegas.com. Dial in details are +44 (0) 2071 928 000 (UK and International), +1 631 510 7495 (US) or +47 23 96 02 64 (Norway). Please quote the passcode: 3835678. Phone lines will open 10 minutes before the conference call. For further queries, please contact: Peder C. G. Simonsen CFO Tel: +47 22 00 48 15 Email: firstname.lastname@example.org ABOUT AVANCE GAS Avance Gas Holding Ltd operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs), operating a fleet of 14 modern VLGC. For more information about Avance Gas, please visit: www.avancegas.com This i